Table 4.
Adjuvant chemotherapy and patient/tumour characteristics
| pT1a, pT1b total patients (N = 402) | Patients treated with adjuvant chemotherapy (N = 127)* | |
|---|---|---|
|
Distribution by age |
|
|
| 18–34 |
7/402 (1.7%) |
6/7 (85.7%) |
| 35–49 |
85/402 (21.1%) |
46/85 (54.1%) |
| 50–69 |
230/402 (57.2%) |
67/230 (29.1%) |
| ≥ 70 |
80/402 (19.9%) |
8/80 (10.0%) |
|
Menopausal status |
|
|
| Pre- |
101/402 (25.1%) |
52/101 (51.5%) |
| Post- |
293/402 (72.8%) |
72/293 (24.6%) |
| Unknown |
8/402 (2.0%) |
3/8 (37.5%) |
|
Grading |
|
|
| G1 |
101/402 (25.1%) |
9/101 (8.9%) |
| G2 |
221/402 (55.0%) |
66/221 (29.8%) |
| G3 |
72/402 (17.9%) |
49/72 (68.0%) |
| Unknown |
8/402 (2.0%) |
3/8 (37.5%) |
|
Proliferation index (Ki-67/MB1) |
|
|
| 0–18% |
283/402 (70.6%) |
55/283 (19.4%) |
| 19–29% |
52/402 (12.9%) |
28/53 (52.8%) |
| ≥ 30% |
54/402 (13.4%) |
41/54 (75.9%) |
| Unknown |
13/402 (3.2%) |
3/13 (23.0%) |
|
ER status |
|
|
| ER positive (≥ 10%) |
351 /402(87.3%) |
82/351(23.6%) |
| ER negative (0–9%) |
51/402(12.7%) |
45/51 (88.2%) |
|
Hormonal status* |
|
|
| ER and/or PgR positive |
354 /402 (74.6%) |
84/354 (24.0%) |
| ER and PgR negative |
48/402 (25.4%) |
43/48 (89.6%) |
|
HER2 status** |
|
|
| Positive |
49/402 (12.2%) |
36/49 (73.5%) |
| Negative |
344/402 (85.6%) |
90/344 (26.2%) |
| Missing |
9/402 (2.2%) |
1/9 (11.1%) |
|
pN status |
|
|
| pN0 |
319/402 (79.4%) |
72/319 (22.6%) |
| pN1 (1–3) |
74/402 (18.4%) |
47/74 (63.5%) |
| pN2 (4–9) |
6/402(1.5%) |
5/6 (83.3%) |
| pN3 (≥ 10) | 3/402 (0.7%) | 3/3 (100%) |
* cut off: 10%
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH